

Atezolizumab

Section	Indications
Immunomodulators	
Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung
Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion	Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Hepatocellular carcinoma of liver

Bevacizumab

Section	Indications
Immunomodulators	
Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion	Hepatocellular carcinoma of liver

Blinatumomab

Section	Indications
Immunomodulators	
Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial	B lymphoblastic leukaemia or lymphoma, not elsewhere classified

Cemiplimab

Section	Indications
Immunomodulators	
Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion	Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Adenocarcinoma of stomach Other specified malignant neoplasms of bronchus or lung

Daratumumab

Section	Indications
Immunomodulators	
Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL	Plasma cell myeloma

Dostarlimab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion	Other specified malignant neoplasms of corpus uteri

Durvalumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion	Other specified malignant neoplasms of bronchus or lung Hepatocellular carcinoma of liver Malignant neoplasms of biliary tract, distal bile duct Malignant neoplasm of intrahepatic bile ducts Malignant neoplasms of gallbladder Malignant neoplasms of proximal biliary tract, cystic duct

Filgrastim

Section	Indications
Immunomodulators Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial	Acquired neutropaenia

Ipilimumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion	Other specified malignant neoplasms of bronchus or lung Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of oesophagus Melanoma of skin

Lenalidomide

Section	Indications
Immunomodulators Oral > Solid: 25 mg	Plasma cell myeloma

Nivolumab

Section

Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to pembrolizumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

Pegfilgrastim

Section

Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

Acquired neutropaenia

Pembrolizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 25 mg per mL in 4 mL vial Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion	Melanoma of skin Malignant neoplasms of cervix uteri Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Adenocarcinoma of stomach Squamous cell carcinoma of hypopharynx and variants Renal cell carcinoma of kidney, except renal pelvis Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx Squamous cell carcinoma of oropharynx Carcinoma of breast, specialised type Squamous cell carcinoma of nasopharynx Squamous cell carcinoma of oesophagus Malignant neoplasms of oesophagogastric junction Therapeutic equivalent to nivolumab for Melanoma of skin

Thalidomide

Section	Indications
Immunomodulators Oral > Solid: 50 mg	Plasma cell myeloma

Tislelizumab

Section	Indications
Immunomodulators Parenteral > General injections > IV: 100 mg per 10 mL Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion	Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung Squamous cell carcinoma of oesophagus

Toripalimab

Section

Immunomodulators

Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

Malignant neoplasms of nasopharynx

Squamous cell carcinoma of oesophagus

Tremelimumab

Section

Immunomodulators

Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

Hepatocellular carcinoma of liver

Other specified malignant neoplasms of bronchus or lung